Back to top
more

Guardant Health (GH)

(Real Time Quote from BATS)

$29.02 USD

29.02
1,818,692

-1.19 (-3.94%)

Updated Nov 15, 2024 03:08 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value B Growth D Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 29% (72 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Guardant Health (GH) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates

by Zacks Equity Research

Although the revenue and EPS for Guardant Health (GH) give a sense of how its business performed in the quarter ended September 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Guardant Health (GH) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

Guardant Health (GH) delivered earnings and revenue surprises of 18.18% and 12.72%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Unveiling Guardant Health (GH) Q3 Outlook: Wall Street Estimates for Key Metrics

by Zacks Equity Research

Evaluate the expected performance of Guardant Health (GH) for the quarter ended September 2024, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.

Will Guardant Health (GH) Report Negative Earnings Next Week? What You Should Know

by Zacks Equity Research

Guardant Health (GH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Liquidia Technologies (LQDA) Soars 14.1%: Is Further Upside Left in the Stock?

by Zacks Equity Research

Liquidia Technologies (LQDA) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Guardant Health (GH) Recently Broke Out Above the 20-Day Moving Average

by Zacks Equity Research

Is it a good or bad thing when a stock surpasses resistance at the 20-day simple moving average?

Guardant Health (GH) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates

by Zacks Equity Research

While the top- and bottom-line numbers for Guardant Health (GH) give a sense of how the business performed in the quarter ended June 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Guardant Health (GH) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Guardant Health (GH) delivered earnings and revenue surprises of 15.79% and 9.45%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

What Analyst Projections for Key Metrics Reveal About Guardant Health (GH) Q2 Earnings

by Zacks Equity Research

Beyond analysts' top -and-bottom-line estimates for Guardant Health (GH), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended June 2024.

Merus N.V. (MRUS) Reports Q2 Loss, Lags Revenue Estimates

by Zacks Equity Research

Merus (MRUS) delivered earnings and revenue surprises of -6.58% and 23.94%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Guardant Health (GH) Moves 6.9% Higher: Will This Strength Last?

by Zacks Equity Research

Guardant Health (GH) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Guardant Health (GH) Just Overtook the 20-Day Moving Average

by Zacks Equity Research

Should investors be excited or worried when a stock crosses above the 20-day simple moving average?

Guardant Health (GH) Now Trades Above Golden Cross: Time to Buy?

by Zacks Equity Research

Is it a good or bad thing when a stock experiences a golden cross technical event?

Guardant Health (GH) Recently Broke Out Above the 200-Day Moving Average

by Zacks Equity Research

When a stock breaks out above the 200-day simple moving average, good things could be on the horizon. How should investors react?

Stock Market News for May 13, 2024

by Zacks Equity Research

U.S. stocks closed mixed on Friday as investors awaited the April Consumer Price Index report, which is influential in shaping the Federal Reserve's interest rate policies, alongside assessing quarterly earnings.

Compared to Estimates, Guardant Health (GH) Q1 Earnings: A Look at Key Metrics

by Zacks Equity Research

Although the revenue and EPS for Guardant Health (GH) give a sense of how its business performed in the quarter ended March 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Guardant Health (GH) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Guardant Health (GH) delivered earnings and revenue surprises of 36.11% and 11.94%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

MannKind (MNKD) Beats Q1 Earnings and Revenue Estimates

by Zacks Equity Research

MannKind (MNKD) delivered earnings and revenue surprises of 150% and 13.76%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

Guardant (GH) Gears Up for Q1 Earnings: Here's What to Expect

by Zacks Equity Research

Investors' focus will likely be on revenues generated by Guardant Health (GH) from its precision oncology testing business.

Curious about Guardant Health (GH) Q1 Performance? Explore Wall Street Estimates for Key Metrics

by Zacks Equity Research

Besides Wall Street's top -and-bottom-line estimates for Guardant Health (GH), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended March 2024.

These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar

by Zacks Equity Research

Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.

Guardant Health (GH) Reports Q4 Earnings: What Key Metrics Have to Say

by Zacks Equity Research

The headline numbers for Guardant Health (GH) give insight into how the company performed in the quarter ended December 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Guardant Health (GH) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

Guardant Health (GH) delivered earnings and revenue surprises of -69.89% and 2.20%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

Wall Street Analysts Think Guardant Health (GH) Could Surge 109.89%: Read This Before Placing a Bet

by Zacks Equity Research

The average of price targets set by Wall Street analysts indicates a potential upside of 109.9% in Guardant Health (GH). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

NeoGenomics (NEO) Q4 Earnings and Revenues Beat Estimates

by Zacks Equity Research

NeoGenomics (NEO) delivered earnings and revenue surprises of 400% and 1.73%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?